Work in our lab Collaborative Projects / Partners -COST CM1106 ACTION -OUR UNIVERSITY...

download Work in our lab Collaborative Projects / Partners -COST CM1106 ACTION -OUR UNIVERSITY COLLABORATORS-our

of 35

  • date post

    25-Oct-2020
  • Category

    Documents

  • view

    0
  • download

    0

Embed Size (px)

Transcript of Work in our lab Collaborative Projects / Partners -COST CM1106 ACTION -OUR UNIVERSITY...

  • Work in our lab Collaborative Projects / Partners

    Ioannis S. Vizirianakis, Ph.D.

    Associate Professor in Molecular Pharmacology & Pharmacogenomics and

    Member of the PharmaInformatics Group at ATHENA Institute, Athens

    3ο Πανελλήνιο Συνέδριο Εφαρµοσµένης Φαρµακευτικής Θεσσαλονίκη, 6-7 Μαΐου 2017

    Laboratory of Pharmacology, Department of Pharmaceutical Sciences,

    Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece

    Σύγχρονη φαρµακολογική ανάπτυξη και χορήγηση καινοτόµων φαρµάκων: Φαρµακευτική έρευνα και ρυθµιστικό

    πλαίσιο 

  • Drug absorption Drug excretion

    Drug metabolismDrug distribution

    Drug transportTransporter proteins

    Metabolizing enzymes

    Drug delivery

    Pharmacology Pre-genomics

    Post-genomics

    Receptors

    Epigenetics

    Genes Drugs

    Drug effects

    Genetic polymorphisms affect drug response

    Drug actions affect gene expression

    Pharmacokinetics

    Pharmacodynamic s

    Advanced Cell Therapies

    Nanotheranostics

    Imaging Technologies Molecularly-targeted Therapeutics Nanomedicine

    Biomaterials

    Protein TherapeuticsRNA Therapeutics

    Molecular Diagnostics

    Pharmacogenetic sPharmacogenomic s

    The challenges for pharmacological research to contribute in the development of efficacy/safety assays thus increasing productivity and the outcome in clinical practice Manuscript under preparation

  • Vizirianakis I.S. (2014). Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned, World J. Pharmacol., 3(4): 110-119.

    Re se

    ar ch

    Cl in

    ic al

    p ra

    ct ic

    e /

    Ph ar

    m ac

    eu ti

    ca l

    ca re

    Ed uc

    at io

    n

  • Pharmacokinetics; PK

    Medicinal Chemistry

    Pharmacology

    Pharmacogenomics; PGx

    Genotyping

    Pharmacotyping

    Relevant knowledge for pharmacy disciplines

  • A CRITICAL POINT OF VIEW For the new drug development and delivery in the post-genomic era

    ΦΑΡΜΑΚΟ: Φαρµακευτικό «περιβάλλον» - «Αξιοποίηση»

    δεδοµένων για πρακτικότητα και παραγωγικότητα

  • Interdisciplinar y new roles

  • COLLABORATIVE WORK – WORKING PROJECTS / PARTNERS

    INNOVATIVE NEW DRUG DEVELOPMENT

    INNOVATIVE DRUG DELIVERY SYSTEMS

    PHYSIOLOGICALLY BASED

    PHARMACOKINETICS (PBPK) MODELS

    Simcyp

    -BNCT PROJECT (Kingston, Portsmouth) -COST CM1106 ACTION -OUR UNIVERSITY COLLABORATORS

    -our work on ribosomal proteins RPS5, RPL35 & beyond -ribosomopathies

    Focus on developing therapeutics with maximum safety and efficacy

    clinical outcomes

    PHARMA-RELATED BIOINFORMATICS

    TOOLS DEVELOPMENT

    Attention given on developing methodologies applicable to preclinical drug regulatory

    development and delivery eras Molecular Pharmacology ERYTHROPOIESIS LEUKEMIA RIBOSOMOPATHIES CVD PGx initiative

  • PHARMACOGENOMICS PERSONALIZED/PRECISION MEDICINE

    This conceptual approach is thoroughly covered by my recent edited volume on personalized medicine

  • INNOVATIVE NEW DRUG DEVELOPMENT

  • We work on

    …toward getting improved drug delivery & therapy outcomes..

  • O

    O

    O

    parthenolide potent NF-kB inhibitor

    6Promising anticancer

    agent

    Leads for Anticancer Drugs?

    scan for new leads

    12

    same core novel substitution

    Συλλογική Σύνθεση Σεσκιτερπενοειδών µε Στόχευση Νέων Αντικαρκινικών Ενώσεων

    Συνθετικές µεθοδολογίες προσέγγισης χηµικών

    βιβλιοθηκών

    Σκοπός Η οµάδα συνθέτει και παρέχει µικρή βιβλιοθήκη βιοδραστικών φυσικών σεσκιτερπενοειδών µε στόχευση σε δοµές υψηλής κυτταροτοξικότητας όπως επίσης και φυσικές δοµές εκλεκτικής στόχευσης καρκινικών Stem Cells. Ήδη στο εργαστήριο έχουν συντεθεί πάνω από 30 νέες δοµές και 4 φυσικά προϊόντα.

    Βασιζόµαστε Στη βιοµιµητική συλλογική σύνθεση και την ανάπτυξη νέων µεθοδολογιών για την ευκολότερη αλλά και αποδοτικότερη παρασκευή βιοδραστικών µορίων πάντα µε βάση αποµονωθέντα φυσικά προϊόντα και παραλλαγµένες δοµές φυσικών προϊόντων.

    Στοχεύοντας σε δοµές αντικαρκινικών ενώσεων

    Δηµιουργία Βιβλιοθηκών διαφοροποιηµένων δοµών µε δοµικά χαρακτηριστικά βασισµένα σε φυσικά προϊόντα µε ισχυρές αντικαρκινικές δράσεις.

    Alexandros Zografos Ph.D. Assistant Professor

    Aristotle University of Thessaloniki

    (http://users.auth.gr/~alzograf/)

    ΣΥΝΕΡΓΑΣΙΑ ΕΡΕΥΝΗΤΙΚΩΝ ΟΜΑΔΩΝ: Ι.Σ. ΒΙΖΙΡΙΑΝΑΚΗΣ & Α. ΖΩΓΡΑΦΟΣ

    http://users.auth.gr/~alzograf/

  • Assessing the pharmacological profile of new synthetic

    sesquiterpene VDS58 that activates p21 gene expression in cancer cells

    Melpomeni Akrivou1 , Vera Demertzidou2 , Nikoleta Theodoroula1 , Nikolaos

    Grigoriadis3,4, Alexandros Zografos2 , Ioannis Vizirianakis1

    1Department of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece 2Department of Chemistry, Laboratory of Organic Chemistry, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece 3Genetics and IVF Unit, Department of Obstetrics and Gynaecology, Medical School, Ioannina University, Ioannina, Greece 4Biogenea Pharmaceuticals Cord Blood Bank, Thessaloniki, Greece

    Manuscript under preparation

  • Ι.Σ. ΒΙΖΙΡΙΑΝΑΚΗΣ Εργαστήριο Φαρµακολογίας, Τοµέας Φαρµακολογίας, Τµήµα Φαρµακευτικής

    Αριστοτέλειο Πανεπιστήµιο Θεσσαλονίκης

  • In parallel to this work, an attempt is under way to overcome formulation problems of these compounds for preclinical assessment in animal models and/or upon potential drug delivery

    Carboranes for BNCT Cancer Therapy

    Boron Neutron Capture Therapy (BNCT)

  • INNOVATIVE DRUG DELIVERY SYSTEMS

  • Our recent work on innovative oral drug delivery systems…

  • (A) BEA and (B) NaX-FAU particles

    Diffusion of 5-FU through the channel system of (C) BEA and (D) NaX-FAU (Simulation)

    steep release

    multi-step release profile

    faster

    slower

    Faujasite framework (FAU) Beta polymorph A, disordered framework, (BEA)

  • PHYSIOLOGICALLY BASED PHARMACOKINETICS (PBPK)

    MODELS Simcyp

  • Enhancing translational capacity in being able to implement in vivo pharmacology with multivariate factors including genomics in a focused drug prescription way for a given individual or a specific group of patients….

    PTxPBPK models – Participation into the Simcyp® consortium…..

    In vivo pharmacology / Systems pharmacology…

    pp. 685-726

    2001

  • Vizirianakis IS, Mystridis GA, Avgoustakis K, Fatouros DG, Spanakis M. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics. Oncol Rep. 2016 Apr;35(4): 1891-904. doi: 10.3892/or.2016.4575.

    Proposed Physiologically-based Pharmacokinetic Model for Cancer Nanomedicine and Pharmacogenomics

    (PBPK-NM)

    https://www.ncbi.nlm.nih.gov/pubmed/26781205

  • PHARMA-RELATED BIOINFORMATICS TOOLS DEVELOPMENT

    Society “Hellenic Bioinformatics” Συνέδριο Hbio 09 / November 19-21 November 2016, Thessaloniki

    https://hscbio.wordpress.com/conferences-when/2016-09/

    https://hscbio.wordpress.com/conferences-when/2016-09/

  • ERYTHROPOIESIS LEUKEMIA

    RIBOSOMOPATHIES, etc

    -Our work on ribosomal proteins RPS5, RPL35 & beyond

  • Αριστοτέλειο Πανεπιστήµιο Θεσσαλονίκης Τµήµα Φαρµακευτικής

    Εργαστήριο Φαρµακολογίας Ιωάννης Βιζιριανάκης, Ph.D.

  • 1 2 3

    B

    C

    rpS5

    β-actin

    primers

    primers

    RPS5

    D

    1 2 3 4

    tubulin

    E

    In du

    ct io